From: The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
Synaptotagmin, 215–223 | Synaptotagmin, 238–245 | |
---|---|---|
Sample set I, control (N = 17) | ||
Age | N.S. | N.S. |
MMSE | N.S. | N.S. |
Amyloid-β1–42 (ng/L) | rho = 0.515, P = 0.04 | N.S. |
Total tau (ng/L) | rho = 0.739, P = 0.001 | rho = 0.749, P = 0.001 |
Phosphorylated tau (ng/L) | rho = 0.770, P = 0003 | rho = 0.708, P = 0.001 |
Synaptotagmin, 215–223 | – | rho = 0.971, P < 0.00001 |
Synaptotagmin, 238–245 | rho = 0.971, P < 0.00001 | – |
Alzheimer’s disease dementia (N = 17) | ||
Age | N.S. | N.S. |
MMSE | N.S. | N.S. |
Amyloid-β1–42 (ng/L) | N.S. | N.S. |
Total tau (ng/L) | rho = 0.540, P = 0.03 | rho = 0.610, P = 0.009 |
Phosphorylated tau (ng/L) | rho = 0.586, P = 0.01 | rho = 0.656, P = 0.004 |
Synaptotagmin, 215–223 | – | rho = 0.980, P < 0.00001 |
Synaptotagmin, 238–245 | rho = 0.980, P < 0.00001 | – |
Sample set II, control (N = 36) | ||
Age | N.S. | N.S. |
MMSE | N.S. | N.S. |
Amyloid-β1–42 (ng/L) | rho = 0.381, P = 0.02 | rho = 0.348, P = 0.04 |
Total tau (ng/L) | rho = 0.641, P = 0.00003 | rho = 0.633, P = 0.00004 |
Phosphorylated tau (ng/L) | rho = 0.687, P < 0.00001 | rho = 0.683, P < 0.00001 |
Synaptotagmin, 215–223 | – | rho = 0.995, P < 0.00001 |
Synaptotagmin, 238–245 | rho = 0.995, P < 0.00001 | – |
MCI-AD (N = 18) | ||
Age | N.S. | N.S. |
MMSE | N.S. | N.S. |
Amyloid-β1–42 (ng/L) | N.S. | N.S. |
Total tau (ng/L) | N.S. | N.S. |
Phosphorylated tau (ng/L) | N.S. | N.S. |
Synaptotagmin, 215–223 | – | rho = 0.988, P < 0.00001 |
Synaptotagmin, 238–245 | rho = 0.988, P < 0.00001 | – |
Alzheimer’s disease dementia (N = 24) | ||
Age | N.S. | N.S. |
MMSE | N.S. | N.S. |
Amyloid-β1–42 (ng/L) | N.S. | N.S. |
Total tau (ng/L) | rho = 0.655, P = 0.001 | rho = 0.675, P = 0.0003 |
Phosphorylated tau (ng/L) | rho = 0.653, P = 001 | rho = 0.673, P = 0.0003 |
Synaptotagmin, 215–223 | – | rho = 0.995, P < 0.00001 |
Synaptotagmin, 238–245 | rho = 0.995, P < 0.00001 | – |